RxDoctor Payments Data

Paula Warren, MD

Neurology · Hattiesburg, MSNPI 1932336302

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $92,979 of the $114,302 with a category attached, or 81.3%. 59 manufacturers reported payments, led by AbbVie at 50.0% of the total. 2025 is the largest year on record at $62,482, more than ten times the $1,947 reported in 2019. Among neurology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$114,302in general payments, 2019–2025

Across 626 payments — averaging $182.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$57K
  • Pfizer$50K
  • Teva Pharmaceuticals USA, Inc.$565
  • Amgen$426
  • UCB, Inc.$381
  • Acadia Pharmaceuticals Inc$367
  • plus $5K from 53 others

What the payments were for

  • Consulting fees$1,9502%
  • Speaking & faculty fees$92,97981%
  • Travel & lodging$8,8598%
  • Food & beverage$10,5139%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)144$57,178
Pfizer66$49,982
Teva Pharmaceuticals USA, Inc.35$565
Amgen(2 entities)25$426
UCB, Inc.25$381
Acadia Pharmaceuticals Inc25$367
Biogen14$341
AstraZeneca(2 entities)22$337
Lundbeck LLC18$319
Lilly USA, LLC20$314
Sunovion Pharmaceuticals Inc.16$262
Sanofi12$223
Eisai Inc.13$216
Avanir Pharmaceuticals, Inc.12$181
Novocure Inc.4$181
SK Life Science, Inc.8$175
Merck7$154
Johnson & Johnson(2 entities)9$152
Novartis8$144
Genentech USA, Inc.10$139
Neurocrine Biosciences, Inc.8$139
EMD Serono, Inc.10$138
CSL Behring8$136
Biohaven Pharmaceutical Holding Company Ltd.7$122
Biohaven Pharmaceuticals, Inc.10$112
GE HealthCare7$108
Upsher-smith Laboratories LLC7$103
Kyowa Kirin, Inc.6$100
Supernus Pharmaceuticals, Inc.6$97
Deciphera Pharmaceuticals Inc.4$89
Octapharma USA, Inc.4$89
Adamas Pharmaceuticals, Inc.5$85
Daiichi Sankyo Inc.4$79
Acorda Therapeutics, Inc4$71
Incyte Corporation4$69
Gilead(2 entities)3$68
Mallinckrodt Enterprises LLC4$64
Grifols USA, LLC3$51
Sobi, Inc2$51
Bayer2$45
Alnylam Pharmaceuticals Inc.2$43
Takeda Pharmaceuticals U.S.A., Inc.2$39
Scilex Pharmaceuticals Inc.2$38
Amneal Pharmaceuticals LLC3$36
Merz Pharmaceuticals, LLC2$28
GSK1$26
Jazz Pharmaceuticals Inc.1$25
Foundation Medicine, Inc.1$25
Spectrum Pharmaceuticals Inc.1$20
AVEO Pharmaceuticals, Inc.1$20
Fresenius Kabi USA, LLC1$19
Arbor Pharmaceuticals, Inc.1$19
ADC Therapeutics America, Inc.1$18
Akcea Therapeutics, Inc.1$17
G1 Therapeutics, Inc.1$17
Bristol Myers Squibb1$16
Cumberland Pharmaceuticals, Inc.1$16
Mirati Therapeutics, Inc.1$15
Rigel Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,302 in reported general payments places this provider in the 95th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$139,555
Medicare patients
115
Services billed
12,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant31$38,969
QuliptaAtogepant30$37,883
Nurtec OdtRimegepant Sulfate22$34,555
BotoxOnabotulinumtoxina19$24,555
AptiomEslicarbazepine Acetate11$19,925
EliquisApixaban11$6,364
Levetiracetam24$1,358
Oxcarbazepine13$950
Lacosamide39$922
Gabapentin90$619
Dexamethasone36$559
Donepezil Hcl36$286
Sumatriptan Succinate16$189
Lamotrigine15$173
Venlafaxine Hcl ErVenlafaxine Hcl13$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$57,178$101,40880 claims
PfizerNurtec Odt, Eliquis$49,982$40,92033 claims
Sunovion Pharmaceuticals Inc.Aptiom$262$19,92511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 neurology providers in Mississippi.

Other neurology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →